Tizanidne Hydrochloride Capsule
Product Images NDC 71335-2208

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidne Hydrochloride (NDC 71335-2208). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352208)

Label for Tizanidine Hydrochloride Capsules, 2 mg strength. The label shows 150 capsules per container, marked Rx only. It features the Bryant Ranch Prepack logo and states the product is relabeled by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Alkem Laboratories Ltd. Storage instructions and drug warnings are also included along with the NDC number 71335-2208-1.*

FDA Label Image

Tiz01 (Tiz01)

Chemical structure of Tizanidne Hydrochloride showing the arrangement of atoms, including chlorine (Cl), nitrogen (N), sulfur (S), and the hydrochloride (HCl) component.*

FDA Label Image

Tiz02 (Tiz02)

A pharmacokinetic graph showing plasma Tizanidine concentration (ng/mL) over time (hours) after dosing. The chart compares concentration curves for 2 mg and 4 mg Tizanidine tablets and capsules with and without food, illustrating absorption and elimination profiles over a 24-hour period.*

FDA Label Image

Tiz03 (Tiz03)

A line graph showing improvement in Ashworth Score over time (hours post-dose) for 16 mg tizanidine, 8 mg tizanidine, and placebo groups. The vertical axis represents improvement scores, and the horizontal axis shows time from 0 to 6 hours. Data include error bars indicating variability.*

FDA Label Image

Tiz04 (Tiz04)

A line graph depicting improvement in Ashworth Score over time for Tizanidine (mean dose 28.8 mg) versus placebo. The x-axis shows three study points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). The y-axis represents improvement scores ranging from -6 to 2, with Tizanidine showing greater improvement (negative scores) compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.